Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $2,212,620.90 in Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) insider Pamela J. Cramer sold 49,006 shares of Rhythm Pharmaceuticals stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $45.15, for a total transaction of $2,212,620.90. Following the sale, the insider now directly owns 13,500 shares in the company, valued at approximately $609,525. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Rhythm Pharmaceuticals Stock Performance

Shares of RYTM opened at $46.70 on Friday. The firm’s 50-day simple moving average is $44.81 and its two-hundred day simple moving average is $42.84. Rhythm Pharmaceuticals, Inc. has a fifty-two week low of $20.97 and a fifty-two week high of $53.92. The stock has a market cap of $2.85 billion, a PE ratio of -10.09 and a beta of 2.04.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.55) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.16. The firm had revenue of $29.08 million for the quarter, compared to analysts’ expectations of $28.79 million. Rhythm Pharmaceuticals had a negative net margin of 254.88% and a negative return on equity of 221.65%. The business’s revenue for the quarter was up 51.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.82) earnings per share. Equities research analysts predict that Rhythm Pharmaceuticals, Inc. will post -4.4 EPS for the current year.

Analyst Ratings Changes

RYTM has been the topic of a number of research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $55.00 target price on shares of Rhythm Pharmaceuticals in a research note on Wednesday, August 7th. Wells Fargo & Company cut their target price on shares of Rhythm Pharmaceuticals from $53.00 to $52.00 and set an “overweight” rating on the stock in a research note on Thursday, April 18th. Bank of America lowered shares of Rhythm Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $49.00 to $42.00 in a research note on Wednesday, May 8th. Finally, Canaccord Genuity Group dropped their price objective on shares of Rhythm Pharmaceuticals from $80.00 to $79.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Rhythm Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $55.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CWM LLC lifted its position in Rhythm Pharmaceuticals by 62.6% during the second quarter. CWM LLC now owns 657 shares of the company’s stock valued at $27,000 after purchasing an additional 253 shares during the period. AJOVista LLC purchased a new position in Rhythm Pharmaceuticals during the fourth quarter valued at $42,000. ORG Partners LLC purchased a new position in shares of Rhythm Pharmaceuticals in the 2nd quarter worth $51,000. Nisa Investment Advisors LLC grew its stake in shares of Rhythm Pharmaceuticals by 91.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,256 shares of the company’s stock worth $58,000 after buying an additional 600 shares in the last quarter. Finally, Quest Partners LLC lifted its holdings in shares of Rhythm Pharmaceuticals by 513.3% in the 2nd quarter. Quest Partners LLC now owns 1,662 shares of the company’s stock worth $68,000 after acquiring an additional 1,391 shares during the last quarter.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.